Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Methodological standard · §6

CEI-MS-12 — worked example

A worked calculation, and an illustrative mass balance showing what a purity figure alone does not establish.

Document identifier
CEI-MS-12/6
Series
Methodological standard
Version
1.0
Published
18 Nov 2024
Last reviewed
18 Mar 2025
Next review
18 Mar 2028
Identifier
10.71829/cei.meth.11
Certainty
High
Cycle
2024 Q4
Category
Content

§6Worked example

§6.1Worked example — converting a permitted daily exposure into a concentration limit

  1. Dichloromethane is an ICH class 2 solvent with a permitted daily exposure of 6.0 mg per day.
  2. For a compound with a maximum daily dose of 10 mg, the concentration limit is the permitted daily exposure divided by the daily dose: 6.0 mg ÷ 0.010 g = 600 mg/g, that is 600 000 ppm. The limit is not restrictive at this dose.
  3. For a compound with a maximum daily dose of 2 g, the limit becomes 6.0 mg ÷ 2 g = 3.0 mg/g = 3 000 ppm, which is the ICH default option-1 limit for dichloromethane and is restrictive.
  4. The instructive point is that residual-solvent limits scale inversely with dose, so a limit that is irrelevant for a milligram-dosed peptide becomes controlling for a gram-dosed excipient. A report stating a solvent concentration without the dose against which the limit was calculated has not established compliance, exactly as with the endotoxin calculation in CEI-MS-05.

§6.2Illustrative mass balance

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q3C(R9) Impurities: Guideline for Residual Solvents. ICH Harmonised Guideline 2024;Step 4 version. identifier not held by the Institute
  2. United States Pharmacopeial Convention. General Chapter ⟨1225⟩ Validation of Compendial Procedures. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.